(Q36075065)

12 August 2017

1 reference

title

Assessment of disease progression in motor neuron disease (English)

1 reference

12 August 2017

4

Matthew C Kiernan

1 reference

12 August 2017

Jennica M C Winhammar

series ordinal

1

1 reference

PubMed ID

15778102

12 August 2017

Dominic B Rowe

series ordinal

2

1 reference

PubMed ID

15778102

12 August 2017

Robert D Henderson

series ordinal

3

1 reference

12 August 2017

1 April 2005

1 reference

12 August 2017

1 reference

12 August 2017

4

1 reference

12 August 2017

4

1 reference

12 August 2017

229-238

1 reference

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Current management of ALS: Comparison of the ALS CARE Database and the AAN Practice Parameter

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Molecular and cellular mechanism of glutamate receptors in relation to amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

The natural history of amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Flail arm syndrome: a clinical variant of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Flail arm syndrome: a distinctive variant of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases a

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria. rhCNTF ALS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Reliability of the El Escorial diagnostic criteria for amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Early symptom progression rate is related to ALS outcome: a prospective population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

The spectrum of chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

1 reference

7 January 2021

Motor Neuropathy with Proximal Multifocal Persistent Conduction Block, Fasciculations and Myokymia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Multifocal motor neuropathy with conduction block: a study of 24 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Natural history of 46 patients with multifocal motor neuropathy with conduction block

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Juvenile muscular atrophy of unilateral upper extremity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Cytoplasmic body myopathy masquerading as motor neuron disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

The Neurophysiological Index in ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Clinical and neurophysiological evaluation of progression in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Measurement of isometric muscle strength: a reproducibility study of maximal voluntary contraction in normal subjects and amyotrophic lateral sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Motor unit number estimation in human neurological diseases and animal models

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Statistical motor unit number estimation: from theory to practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Estimation of the number and size of human flexor digiti minimi muscle motor units using histological methods

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Validity of electromyograms and tension as a means of motor unit number estimation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Electrophysiological estimation of the number of motor units within a human muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

The numbers and relative sizes of motor units estimated by computer

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Methods for estimating the number of motor units in human muscles

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Motor unit number estimates based on the automated analysis of F-responses

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Motor unit estimation: reproducibility of the spike-triggered averaging technique in normal and ALS subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Thenar motor unit number estimates using the multiple point stimulation technique: reproducibility studies in ALS patients and normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Number and relative size of thenar motor units in ALS patients: application of the adapted multiple point stimulation method.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Number and size of motor units in thenar muscles

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Estimating the number of motor units in a muscle.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Comparison of multiple point and statistical motor unit number estimation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Reducing intersubject variability in motor unit number estimation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Effect of changing data collection parameters on statistical motor unit number estimates

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

The use of statistical MUNE in a multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Motor unit number estimate-based rates of progression of ALS predict patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Excitability of human axons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Axonal ion channel dysfunction in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Abnormal axonal inward rectification in diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Strength-duration properties of sensory and motor axons in amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Multiple measures of axonal excitability: a new approach in clinical testing

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Excitability properties of motor axons in patients with spontaneous motor unit activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Nerve excitability properties in lower-limb motor axons: evidence for a length-dependent gradient

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

The corticomotor threshold is not dependent on disease duration in amyotrophic lateral sclerosis (ALS).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Transcranial magnetic stimulation: pro.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Cortical silent period in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Clinical neurophysiology of ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Peristimulus time histograms (PSTHs)--a marker for upper motor neuron involvement in ALS?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Functional scales: Summary

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

The administration of guanidine in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Functional scales: Pro

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Functional scales in ALS: Cons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

A rating scale for amyotrophic lateral sclerosis: description and preliminary experience

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

1 reference

7 January 2021

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

MR spectroscopy in amyotrophic lateral sclerosis/motor neuron disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Pentoxifylline reduces biochemical markers of ischemia-reperfusion induced spinal cord injury in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Therapeutic developments in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Natural history of amyotrophic lateral sclerosis in a database population Validation of a scoring system and a model for survival prediction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Correlates of suffering in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Major stressors facing patients with amyotrophic lateral sclerosis (ALS): a survey to identify their concerns and to compare with those of their caregivers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

A cross sectional study on determinants of quality of life in ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Factors supporting quality of life over time for individuals with amyotrophic lateral sclerosis: the role of positive self-perception and religiosity.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Individual quality of life is not correlated with health-related quality of life or physical function in patients with amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Spirometry in Amyotrophic Lateral Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Pulmonary function at diagnosis of amyotrophic lateral sclerosis. Rate of deterioration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Expiratory muscle function in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Measurement of respiratory muscle strength

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Effects of alterations in pulmonary function and sleep variables on survival in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Polysomnographic studies in amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Breathing pattern and respiratory mechanics in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Sniff nasal inspiratory pressure. A noninvasive assessment of inspiratory muscle strength

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Sniff nasal inspiratory pressure as a marker of respiratory function in motor neuron disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Sleep disorders and diaphragmatic function in patients with amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Respiratory disorders in ALS: sleep and exercise studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Treating respiratory failure in ALS: the details are becoming clearer.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

The central nervous system in motor neurone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Review neuroimaging in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Diffusion tensor MRI assesses corticospinal tract damage in ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Amyotrophic lateral sclerosis: correlation of clinical and MR imaging findings

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Brain and spinal cord MRI in motor neuron disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

High signal intensity on T1 weighted MRI of the anterolateral column of the spinal cord in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

A decrease in cerebral cortex intensity on T2-weighted with ageing images of normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Magnetic resonance imaging in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

The apparent diffusion coefficient of water in gray and white matter of the infant brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Imaging: MRS/MRI/PET/SPECT: summary.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Diffusion tensor imaging and axonal tracking in the human brainstem

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Diffusion tensor imaging detects corticospinal tract involvement at multiple levels in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Cortical function in progressive lower motor neuron disorders and amyotrophic lateral sclerosis: a comparative PET study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Preliminary results of proton magnetic resonance spectroscopy in motor neurone disease (amytrophic lateral sclerosis)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

A proton magnetic resonance spectroscopic study in ALS: correlation with clinical findings.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Alzheimer's disease: diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Amyotrophic lateral sclerosis: objective upper motor neuron markers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fingerprints of disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970042-9

7 January 2021

10.1016/S1474-4422(05)70042-9

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15778102